OncoMatch/Clinical Trials/NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Is NCT06646276 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including BMS-986489 (BMS-986012+Nivolumab) and Atezolizumab for extensive-stage small cell lung cancer.
Treatment: BMS-986489 (BMS-986012+Nivolumab) · Atezolizumab · Carboplatin · Etoposide — The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Small Cell Lung Cancer
Disease stage
Required: Stage IV
diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Prior therapy
Cannot have received: any treatment for extensive stage small cell lung cancer
already received certain types of treatment for extensive stage small cell lung cancer
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Southern Cancer Center, PC · Daphne, Alabama
- Local Institution - 0283 · Hot Springs, Arkansas
- Florida Cancer Specialists - South · Fort Myers, Florida
- Mid Florida Hematology and Oncology Center · Orange City, Florida
- Florida Cancer Specialists - North · St. Petersburg, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06646276 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages